Search Results

"Geneva, Switzerland, August 15, 2022 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical

Confo Therapeutics today announced that it has entered into a collaborative agreement with Regeneron Pharmaceuticals

Poon to Board of Directors Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing - Natural Sciences - Surgery NEW Senior Scientist- Membrane Technologies NEW Computational Protein Design

Switzerland, December 17, 2021 – Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical

Industry News Josephine (Pina) Cardarelli from GPCR Therapeutics on Beyond Biotech Podcast Crinetics Pharmaceuticals PhD student at the Department of Drug Design and Pharmacology Computational drug design postdoc at the Department of Drug Design and Pharmacology Software / database development PhD student at Department of Drug Design and Pharmacology Software / database development postdoc at the Department of Drug Design and Pharmacology Postdoc in Bioinformatics/Data Science at Department of Drug Design and Pharmacology

inactive conformation using molecular dynamic simulations "The δ-opioid receptor (DOR) is a critical pharmaceutical

Methods & Updates in GPCR Research Computational design of dynamic receptor-peptide signaling complexes Industry News X4 Pharmaceuticals Announces $65 Million Private Placement Priced At-the-Market Andrew

She entered undergrad set on becoming a pharmacist. kind of had an identity crisis because I think I realized in that moment that I didn't want to be a pharmacist She gained exposure to in vivo models, immunology, and complex study design, while also getting closer

Switzerland, July 22, 2022 – Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical

to Consider Enrolling Now: Exceptional Educational Opportunities at Unbeatable Value Our courses are designed October 7th to 13th, 2024 Industry News Antiverse Raises £3.5M ($4.6M) to Advance Generative AI Antibody Design Platform GPCR Safety Panels Launched Crinetics Pharmaceuticals Announces October 2024 Inducement Grants

However, AlphaFold3 faces challenges with synthetic ligands, which are central to pharmaceutical development

given the Society’s conference will be held in Perth next year, in collaboration with the Australasian Pharmaceutical

exclusively to our Premium Members this week: Industry insights:  Discover the latest strategic moves in the pharmaceutical Designed for GPCR scientists and translational teams, Premium keeps you informed on the science, careers

Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1117567 in Healthy Adults Crinetics Pharmaceuticals Update Nxera Pharma Operational Highlights and Consolidated Results for the First Quarter 2024 Crinetics Pharmaceuticals

Sosei Heptares Acquires Idorsia’s Pharmaceuticals Business in Japan and APAC (ex-China), Accelerating Specialist - Natural Sciences - Surgery Senior Scientist- Membrane Technologies Computational Protein Design

Reports Financing Highlights Neurocrine Biosciences Provides Development Pipeline Update Crinetics Pharmaceuticals Team Leader Antibody Discovery Staff Scientist (AC-TAP) in Database Development at Department of Drug Design

Submit your logo design by November 1st. You don't need to be registered to participate. Research Associate Research Technician Senior Research Associate, In Vitro Pharmacology - Crinetics Pharmaceuticals

Submit your design by August 15, 2024, and stand a chance to have your creation represent this prestigious strong sales growth and core margin expansion in Q2; raises FY 2024 bottom-line guidance Crinetics Pharmaceuticals

polarization during bacterial infection Industry News InterAx Biotech's AI platform unlocks new drug designs for diabetes, obesity, and cancer Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2023

17th, 2024 Industry News Centessa Launches Phase 2 Trial of ORX750 for Narcolepsy and IH Crinetics Pharmaceuticals chemoresistance by mediating glucose metabolic symbiosis GPCR Binders, Drugs, and more Kinetic Basis for the Design

Logo Contest: Unleash your creativity by designing the event logo! QRFP receptor GPR103 Industry News EY Announces Scott Struthers, Ph.D., CEO and Founder of Crinetics Pharmaceuticals

develop new therapies for people living with obesity, diabetes and other serious metabolic diseases X4 Pharmaceuticals

Mark discussed this position with Beth Fleck, Director of In Vitro Pharmacology at Crinetics Pharmaceuticals proteins Identification of Gα12-vs-Gα13-coupling determinants and development of a Gα12/13-coupled designer

Voyager’s GBA1 Program and Other Next-Generation Gene Therapies for Neurological Diseases Crinetics Pharmaceuticals

all symptoms of schizophrenia Sosei Heptares to receive US$2.5 million milestone payment from Formosa Pharmaceuticals

Structural analysis of the human C5a-C5aR1 complex using cryo-electron microscopy Industry News Crinetics Pharmaceuticals

in nearly all physiological systems make GPCR the largest protein family targeted for development of pharmaceuticals

spinning GPR68 small molecules into GIO New treatments being developed for schizophrenia Crinetics Pharmaceuticals

Jack Antel to its clinical advisory board Crinetics Pharmaceuticals First Quarter 2023 Earnings: Revenues

discussed this exciting opportunity with Beth Fleck, Director of In Vitro Pharmacology at Crinetics Pharmaceuticals